Skip to content
value.today

Marina Biotech, Inc.

Total raised
$20 M
4 rounds on record
Latest round
$2 M
Jul 2018
First round on record
Mar 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Marina Biotech, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2018$2 MNo. 4Under $2 million

Marina Biotech, Inc.: Raise no. 4, Jul 2018

Investors in this round

9 investors had bought by the notice of Jul 25, 2018: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $11 M offered; $9 M still to sell
Smallest investment taken
$30,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$154,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amit A. Shah · Executive Officer
  • Erik A. Emerson · Executive Officer, Director
  • Robert C. Moscato · Executive Officer, Director
  • Donald A. Williams · Director
  • Issac C. Blech · Director
  • Tim A. Boris · Director
  • Uli C. Hacksell · Director
  • Vuong C. Trieu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in AL, CA, MD, MN, NC, NY, PA, WI, and outside the US

Remarks in the notice

  • On fees: “Maxim will also receive a warrant to purchase shares of common stock equal to 10% of the number of shares issuable upon conversion of the preferred stock sold in the offering, as well as additional commissions on any further sales in the offering.”
  • On the use of proceeds: “A Portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”

Signed by Robert C. Moscato, Jr., Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 25, 2018. Read the notice at the SEC.

equity, optionsSEC
Apr 2018$12 MNo. 3$10 to $50 million

Marina Biotech, Inc.: Raise no. 3, Apr 2018

Investors in this round

97 investors had bought by the notice of Apr 26, 2018: 97 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $15 M offered; $3 M still to sell
Smallest investment taken
$20,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,167,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amit A. Shah · Executive Officer
  • Joseph W. Ramelli · Executive Officer
  • Vuong Trieu · Executive Officer, Director
  • Donald A. Williams · Director
  • Issac A. Blech · Director
  • Philip C. Ranker · Director
  • Philippe A. Calais · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “Maxim will also receive a warrant to purchase shares of common stock equal to 10% of the number of shares issuable upon conversion of the preferred stock sold in the offering. Maxim will receive additional commissions on any further sales in the offering.”
  • On the use of proceeds: “A Portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”

Signed by Vuong Trieu, Executive Chairman. Source: SEC Form D, newest notice filed Apr 26, 2018. Read the notice at the SEC.

equity, optionsSEC
Aug 2015$1 MNo. 2Under $2 million

Marina Biotech, Inc.: Raise no. 2, Aug 2015

Investors in this round

3 investors had bought by the notice of Aug 12, 2015: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$100,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • J. Michael French · Executive Officer, Director
  • Donald A. Williams · Director
  • Joseph W. Ramelli · Director
  • Philip C. Ranker · Director
  • Stefan C. Loren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Michael French, President and CEO. Source: SEC Form D, newest notice filed Aug 12, 2015. Read the notice at the SEC.

equity, optionsSEC
Mar 2014$6 MNo. 1$2 to $10 million

Marina Biotech, Inc.: Raise no. 1, Mar 2014

Investors in this round

2 investors had bought by the notice of Mar 13, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
$500,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • J. Michael French · Executive Officer, Director
  • Joseph W. Ramelli · Director
  • Philip C. Ranker · Director
  • Stefan C. Loren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Michael French, President & CEO. Source: SEC Form D, newest notice filed Mar 13, 2014. Read the notice at the SEC.

equity, optionsSEC
Jul 2010$44 MIssued in a merger or acquisition$10 to $50 million

Marina Biotech, Inc.: Private sale, Jul 2010

Investors in this round

25 investors had bought by the notice of Aug 5, 2010: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$44 M of $44 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barry S. Polisky · Executive Officer
  • J. Michael French · Executive Officer, Director
  • Peter S. Garcia · Executive Officer
  • Chiang J. Li · Director
  • Gregory M. Sessler · Director
  • James M. Karis · Director
  • Michael D. Taylor · Director
  • Peter D. Parker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Canaccord Genuity Inc. (CRD 1020) · Boston, MassachusettsSold in CA, MA, NC, NY

Remarks in the notice

  • On the amounts: “The Issuer issued 9,882,853 shares of Common Stock to the stockholders of Cequent Pharmaceuticals at an exchange ratio based on a value of the Common Stock equal to $1.1496.”
  • On a merger: “The shares were issued in connection with the merger of Cequent Pharmaceuticals with and into a wholly-owned subsidiary of the Issuer.”

Signed by Peter S. Garcia, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 5, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Marina Biotech, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2018).

    SEC Form D · Jul 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2018

That is all the official record says: Marina Biotech, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Marina Biotech, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 97 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Marina Biotech, Inc.
NameRoleNamed in
Amit A. ShahExecutive officerJul 2018
Erik A. EmersonExecutive officerJul 2018
Robert C. MoscatoExecutive officerJul 2018
Joseph W. RamelliExecutive officerApr 2018
Vuong TrieuExecutive officerApr 2018
J. Michael FrenchExecutive officerAug 2015
Barry S. PoliskyExecutive officerAug 2010
Peter S. GarciaExecutive officerAug 2010
Donald A. WilliamsDirectorJul 2018
Erik A. EmersonDirectorJul 2018
Issac C. BlechDirectorJul 2018
Robert C. MoscatoDirectorJul 2018
Tim A. BorisDirectorJul 2018
Uli C. HacksellDirectorJul 2018
Vuong C. TrieuDirectorJul 2018
Issac A. BlechDirectorApr 2018
Philip C. RankerDirectorApr 2018
Philippe A. CalaisDirectorApr 2018
Vuong TrieuDirectorApr 2018
J. Michael FrenchDirectorAug 2015
Joseph W. RamelliDirectorAug 2015
Stefan C. LorenDirectorAug 2015
Chiang J. LiDirectorAug 2010
Gregory M. SesslerDirectorAug 2010
James M. KarisDirectorAug 2010
Michael D. TaylorDirectorAug 2010
Peter D. ParkerDirectorAug 2010